FORUS Therapeutics is thrilled to announce Weihao Tang as Senior Product Manager. Weihao brings more than 10 years of experience across the pharmaceutical and clinical diagnostics industries, combining a strong scientific foundation with broad commercial expertise....
FORUS Therapeutics is thrilled to announce Marie-Eve Caron as Associate Director, Sales. Marie-Eve brings more than 20 years of pharmaceutical experience, including over 13 years in specialty care across immunology and hematology/oncology. Throughout her career, she...
(OAKVILLE, Ontario) July 6, 2026 – FORUS Therapeutics Inc (“FORUS”), a wholly owned subsidiary of PharmaEssentia Corp, is pleased to announce that it has received a Notice of Compliance (NOC) authorizing BESREMI® (ropeginterferon alfa-2b) for the treatment of adults...
(OAKVILLE, Ontario) June 11, 2026 – FORUS Therapeutics Inc (“FORUS”) is pleased to announce that it has been acquired by PharmaEssentia Corporation, a global biopharmaceutical company focused on developing innovative therapies for hematology, oncology, and...
We are pleased to announce that Marie-Josèphe Champagne has returned to FORUS as Senior Medical Science Liaison (MSL) for Quebec and Atlantic. Marie-Josèphe brings extensive experience from her recent role as National MSL Manager for Hematology, along with more than a...
FORUS Therapeutics Inc. is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Quebec as of November 6th. Further details on the criteria can be found in the links below: Liste des médicaments – Établissement – en vigueur le 6 novembre...
Recent Comments